70 related articles for article (PubMed ID: 2687812)
1. Recent advances in the management of biotherapy-related side effects: flu-like syndrome.
Haeuber D
Oncol Nurs Forum; 1989; 16(6 Suppl):35-41. PubMed ID: 2687812
[TBL] [Abstract][Full Text] [Related]
2. Physical symptoms of combination biotherapy: a quality-of-life issue.
Brophy LR; Sharp EJ
Oncol Nurs Forum; 1991; 18(1 Suppl):25-30. PubMed ID: 1997974
[TBL] [Abstract][Full Text] [Related]
3. Management strategies for improving the tolerability of interferons in the treatment of multiple sclerosis.
Girouard N; Théorêt G
Can J Neurosci Nurs; 2008; 30(4):18-25. PubMed ID: 19146204
[TBL] [Abstract][Full Text] [Related]
4. Nursing care of patients receiving activated lymphocytes.
Brogley JL; Sharp EJ
Oncol Nurs Forum; 1990; 17(2):187-93. PubMed ID: 2315182
[TBL] [Abstract][Full Text] [Related]
5. Biotherapy: recent advances and nursing implications.
Mayer DK
Nurs Clin North Am; 1990 Jun; 25(2):291-308. PubMed ID: 2186383
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of recombinant interleukin 1alpha and etoposide in patients with relapsed osteosarcoma.
Worth LL; Jaffe N; Benjamin RS; Papadopoulos NE; Patel S; Raymond AK; Jia SF; Rodriguez C; Gano J; Gianan MA; Kleinerman ES
Clin Cancer Res; 1997 Oct; 3(10):1721-9. PubMed ID: 9815556
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
[TBL] [Abstract][Full Text] [Related]
8. Overview of biotherapy and nursing considerations.
Coleman C
J Intraven Nurs; 1998; 21(6):367-73. PubMed ID: 10392103
[TBL] [Abstract][Full Text] [Related]
9. Tolerance of sequential or simultaneous administration of IL-3 and G-CSF in improving peripheral blood stem cells harvesting following multi-agent chemotherapy: a pilot study.
D'Hondt V; Guillaume T; Humblet Y; Doyen C; Chatelain B; Feyens AM; Staquet P; Osselaer JC; Müll B; Symann M
Bone Marrow Transplant; 1994 Mar; 13(3):261-4. PubMed ID: 7515299
[TBL] [Abstract][Full Text] [Related]
10. [Antineoplastic drug and headache].
Hamada J
Brain Nerve; 2008 Feb; 60(2):149-55. PubMed ID: 18306663
[TBL] [Abstract][Full Text] [Related]
11. Biological response modifiers used in cancer biotherapy.
Kuroki M; Miyamoto S; Morisaki T; Yotsumoto F; Shirasu N; Taniguchi Y; Soma G
Anticancer Res; 2012 Jun; 32(6):2229-33. PubMed ID: 22641656
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases.
Paolozzi F; Zamkoff K; Doyle M; Konrad M; Bradley EC; Rudolph A; Newman N; Gullo J; Scalzo A; Poiesz B
J Biol Response Mod; 1989 Apr; 8(2):122-39. PubMed ID: 2786553
[TBL] [Abstract][Full Text] [Related]
13. Tolerance of interferon-alpha therapy in children with chronic hepatitis B.
Liberek A; Łuczak G; Korzon M; Szlagatys-Sidorkiewicz A; Bako W; Góra-Gebka M; Rytlewska M; Sikorska-Wiśniewska G
J Paediatr Child Health; 2004; 40(5-6):265-9. PubMed ID: 15151579
[TBL] [Abstract][Full Text] [Related]
14. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion.
Honkanen H; Piaggio G; Hertzen H; Bártfai G; Erdenetungalag R; Gemzell-Danielsson K; Gopalan S; Horga M; Jerve F; Mittal S; Thi Nhu Ngoc N; Peregoudov A; Prasad RN; Pretnar-Darovec A; Shah RS; Song S; Tang OS; Wu SC;
BJOG; 2004 Jul; 111(7):715-25. PubMed ID: 15198763
[TBL] [Abstract][Full Text] [Related]
15. A perspective on the clinical effectiveness and tolerance of interferon-alpha.
Borden EC; Parkinson D
Semin Oncol; 1998 Feb; 25(1 Suppl 1):3-8. PubMed ID: 9482534
[TBL] [Abstract][Full Text] [Related]
16. Biological response modifiers in cancer therapy.
Gupta S; Kanodia AK
Natl Med J India; 2002; 15(4):202-7. PubMed ID: 12296474
[TBL] [Abstract][Full Text] [Related]
17. [Methods for evaluating biological response modifiers].
Harousseau JL
Bull Cancer; 1998 Dec; 85(12):993-6. PubMed ID: 9917552
[TBL] [Abstract][Full Text] [Related]
18. [Therapy by biological response modifiers].
Urushizaki I
Rinsho Ketsueki; 1989 Aug; 30(8):1230-2. PubMed ID: 2689681
[TBL] [Abstract][Full Text] [Related]
19. A comparison of systemic versus inhaled recombinant IL-2 administration for the treatment of metastatic renal cell carcinoma.
Huland E; Heinzer H; Huland H
Folia Biol (Praha); 2000; 46(6):241-50. PubMed ID: 11140857
[TBL] [Abstract][Full Text] [Related]
20. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
